Last reviewed 2026-05-14 · How we verify

CLDM 1% gel twice daily

GlaxoSmithKline · Phase 3 active Small molecule

CLDM 1% gel twice daily is a Lincosamide antibiotic Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Acne vulgaris (topical treatment), Bacterial skin infections. Also known as: CLDM.

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acne vulgaris (topical treatment), Bacterial skin infections.

At a glance

Generic name	CLDM 1% gel twice daily
Also known as	CLDM
Sponsor	GlaxoSmithKline
Drug class	Lincosamide antibiotic
Target	Bacterial 50S ribosomal subunit
Modality	Small molecule
Therapeutic area	Dermatology
Phase	Phase 3

Mechanism of action

Clindamycin works by binding to the bacterial 50S ribosomal subunit and inhibiting peptide bond formation, thereby preventing bacterial protein synthesis. This bacteriostatic mechanism is effective against a broad range of gram-positive and anaerobic bacteria. The topical gel formulation delivers the antibiotic directly to affected skin areas, making it particularly useful for treating acne and other dermatological infections.

Approved indications

Acne vulgaris (topical treatment)
Bacterial skin infections

Common side effects

Dryness or peeling of skin
Erythema or irritation at application site
Folliculitis
Gram-negative folliculitis (with prolonged use)

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CLDM 1% gel twice daily CI brief — competitive landscape report
CLDM 1% gel twice daily updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about CLDM 1% gel twice daily

What is CLDM 1% gel twice daily?

CLDM 1% gel twice daily is a Lincosamide antibiotic drug developed by GlaxoSmithKline, indicated for Acne vulgaris (topical treatment), Bacterial skin infections.

How does CLDM 1% gel twice daily work?

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

What is CLDM 1% gel twice daily used for?

CLDM 1% gel twice daily is indicated for Acne vulgaris (topical treatment), Bacterial skin infections.

Who makes CLDM 1% gel twice daily?

CLDM 1% gel twice daily is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is CLDM 1% gel twice daily also known as anything else?

CLDM 1% gel twice daily is also known as CLDM.

What drug class is CLDM 1% gel twice daily in?

CLDM 1% gel twice daily belongs to the Lincosamide antibiotic class. See all Lincosamide antibiotic drugs at /class/lincosamide-antibiotic.

What development phase is CLDM 1% gel twice daily in?

CLDM 1% gel twice daily is in Phase 3.

What are the side effects of CLDM 1% gel twice daily?

Common side effects of CLDM 1% gel twice daily include Dryness or peeling of skin, Erythema or irritation at application site, Folliculitis, Gram-negative folliculitis (with prolonged use).

What does CLDM 1% gel twice daily target?

CLDM 1% gel twice daily targets Bacterial 50S ribosomal subunit and is a Lincosamide antibiotic.

Drug class: All Lincosamide antibiotic drugs
Target: All drugs targeting Bacterial 50S ribosomal subunit
Manufacturer: GlaxoSmithKline — full pipeline
Therapeutic area: All drugs in Dermatology
Indication: Drugs for Acne vulgaris (topical treatment)
Indication: Drugs for Bacterial skin infections
Also known as: CLDM
Compare: CLDM 1% gel twice daily vs similar drugs
Pricing: CLDM 1% gel twice daily cost, discount & access